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Abstract 
As  a  steroid  hormone  that  regulates  mineral  homeostasis  and  bone  metabolism,  1α, 
25-dihydroxycholecalciferol  (calcitriol)  also  has  broad  spectrum  anti-tumor  activities  as 
supported by numerous epidemiological and experimental studies. Calcitriol potentiates the 
anti-tumor activities of multiple chemotherapeutics agents including DNA-damaging agents 
cisplatin, carboplatin and doxorubicin; antimetabolites 5-fluorouracil, cytarabine, hydroxyu-
rea, cytarabine and gemcitabine; and microtubule-disturbing agents paclitaxel and docetaxel. 
Calcitriol elicits anti-tumor effects mainly through the induction of cancer cell apoptosis, cell 
cycle arrest, differentiation, angiogenesis and the inhibition of cell invasiveness by a num b e r   o f  
mechanisms. C a l c i t r i o l   e n h a n c e s   t h e   c y t o t o x i c   e f f e c t s   o f   g a m m a   i r r a d i a t i o n   a n d   c e r t a i n   a n-
tioxidants  and  naturally  derived  compounds.  Inhibition  of  calcitriol  metabolism  by 
24-hydroxylase promotes growth inhibition effect of calcitriol. Calcitriol ha s   b e e n   u s e d   i n   a  
n u m b e r   o f   c l i n i c a l   t r i a l s   a n d   i t   i s   i m p o r t a n t   t o   n o t e   t h a t   s u f f i c i e n t   d o s e   a n d   e x p o s u r e   t o   c a l-
citriol is critical to achieve anti-tumor effect. Several trials have demonstrated that safe and 
feasible to administer high doses of calcitriol through intermittent regimen. Further well de-
signed clinical trials should be conducted to better understand the role of calcitriol in cancer 
therapy.  
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Introduction 
V i t a m i n   D   i s   a   s t e r o i d   h o r m o n e   t h a t   r e g u l a t e s  
calcium homeostasis, bone metabolism and a variety 
of other physiological functions (1). V i t a m i n   D   c a n   b e  
obtained from ultraviolet light-induced  photobioge-
nesis  in  the  skin  or  from  the  diet  (1).  In  the  skin, 
7-dehydrocholesterol  is  converted  to  vitamin  D3, 
w h i c h   i s   h y d r o x y l a t e d   t o   2 5 ( O H ) D 3  by 
25-hydroxylase in the liver and then to 1,25(OH)2D3 
(1α,  25-dihydroxycholecalciferol, calcitriol), the hor-
m o n a l l y   a c t i v e   m e t a b o l i t e ,   b y   1 α-hydroxylase in the 
kidney  (1).  Calcitriol  is  mainly  catabolized  by 
24-hydroxylase    (CYP24A1)      to    1α,24,25(OH)2D3 
which loses its bioactivity (1). 
C a l c i t r i o l   a c t s   t h r o u g h   b o t h   g e n o m i c   a n d  
non-genomic mechanisms (2). In genomic pathways, 
calcitriol  binds  to  intracellular  vitamin  D  receptor 
(VDR),  which  subsequently  heterodimerizes  with 
another  nuclear  receptor  retinoid  X  receptor  (RXR). 
The heterodime r   b i n d s   t o   v i t a m i n   D   r e s p o n s e  element 
i n   t a r g e t   g e n e s   a n d   l e a d s   t o   g e n e   t r a n s c r i p t i o n   r e g u-
lation (1). In addition, calcitriol has rapid effects that 
are  independent  of  gene  transcription  regulation, 
which  are  defined  as  non-genomic  effects  and  not 
mediated  directly  through  steroid  recep-
tor-ligand-DNA  interaction.  On  the  other  hand, 
non-genomic actions may indirectly affect gene tran-
scription via the regulation of intracellular signaling 
pathways  that  target  transcription  factors  (3). Calci-
triol induces a number of non-genomic responses in-
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of calcium from intracellular stores, opening of vol-
tage-gated  calcium  and  chloride  channels,  and  the 
activation  o f   p r o t e i n   k i n a s e   C ,   p r o t e i n   k i n a s e   A ,  
phosphatidylinositol-3 kinase (PI3K) and phospholi-
pase C (4). 
Vitamin D compounds in cancer prevention 
and treatment 
Numerous epidemiological and preclinical stu-
dies support a role of vitamin D compounds in cancer 
prevention  and  treatment  in  colorectal,  breast,  pros-
tate, ovarian, bladder, lung and skin cancers and leu-
kemia  (1, 5, 6). Low  levels  of  plasma  25(OH)D3 are 
associated with higher cancer incidence and mortality 
i n   m e n   i n   c o l o r e c t a l ,   b r e a s t ,   l u n g   a n d   p r o s t a t e   c a n c e r s  
(7-10). T h e   b r o a d   s p e c t r u m   a n t i -tumor effects of cal-
citriol and analogs are mostly based on inhibition of 
cancer cell proliferation and invasiveness, induction 
of  differentiation  and  apoptosis,  and  promotion  of 
angiogenesis.  
Calcitriol has been studied in various combina-
tion  treatments  and  shown  synergistic  or  additive 
antitumor  activities.  Cisplatin  (cis-diammine- 
dichloro-platinum (II), cDDP) and its analog carbop-
latin  (Di-amminecyclobutanedicarboxylatoplatinum, 
CBDCA) are widely used DNA-damaging agents. It is 
active in the treatment of testicular, ovarian, cervical, 
lung, bladder cancer and head and neck squamous 
cell carcinoma (SCC) (11, 12). Calcitriol enhances both 
carboplatin and cisplatin-mediated growth inhibition 
i n   b r e a s t   c a n c e r   M C F -7   c e l l s   a n d   p r o s t a t e   c a n c e r  
LNCaP and DU145 cells (13, 14). Calcitriol potentiates 
cisplatin  anti-t u m o r   e f f e c t   i n   a   Y -79 human retinob-
lastoma xenograft model (15) and canine breast can-
cer,  osteosarcoma,  and  mastocytoma  cells  (16). 
Ro23-7553  (1,25(OH)2-16-ene-23-yne-D3),  a  calcitriol 
analog, inhibits tumor regrowth when combined with 
c i s p l a t i n   i n   a   S C C   m o d e l   s y s t e m   (17). Calcitriol pro-
motes  the  expression  of  mitogen-activated  protein 
kinase  kinase  kinase  (MEKK-1 )   a n d   t h e   c l e a v a g e   o f  
c a s p a s e   3   w h e n   u s e d   i n   c o m b i n a t i o n   w i t h   c i s p l a t i n   i n  
SCC cells (18). Additional studies support these find-
ings.  SCC-V I I   a n d   a   c a l c i t r i o l -resistant variant SCC 
(SCC-D R ) ,   g e n e r a t e d   b y   c o n t i n u o u s   c u l t u r i n g   o f   S C C  
cells  in  calcitriol-containing  media  and  has 
non-inducible  VDR,  are  resistant  to  cisplatin  (19). 
Pretreatment  with  calcitriol  sensitizes  SCC  cells  to 
cisplatin-induced  growth  inhibition  and  results  in 
enhanced clonogenic cell kill in SCC. This effect is not 
seen in SCC-D R   c e l l s   i n   v i t r o   a n d   i n   v i v o .  This sensi-
tization may be due to restored apoptotic pathway, as 
indicated by enhanced cleavage of pro-caspase 10 and 
PARP  and  increased  DNA  fragmentation.  Calcitriol 
a n d   c i s p l a t i n   s u p p r e s s   S C C   t u m o r   g r o w t h   m u c h   b e t-
ter than either agent alone (19). Further study shows 
that calcitriol increased the protein   l e v e l   o f   p 7 3 ,   a   p 5 3  
family member, which contributed to calcitriol and 
cisplatin-mediated growth inhibition in SCC cells (19).  
Calcitriol sensitizes breast cancer cells to another 
DNA-damaging agent doxorubicin through the inhi-
bition of the expression and activity of cytoplasmic 
antioxidant  enzyme  Cu/Zn  superoxide  dismutase, 
which  subsequently  increases  the  oxidative  damage 
by  doxorubicin  (20).  Tamoxifen and calcitriol or its 
analog EB1089, KH1060, CB966 or OCT used together 
lead to enhanced growth inhibition in breast cancer 
cells  MCF-7  than  either  agent  alone  (21).  OCT  and 
tamoxifen also inhibit MCF-7   x e n o g r a f t   t u m o r   p r o-
gression (22). 
Calcitriol also additively or synergistically po-
tentiates  the  anti-tumor  activity  of  other  types  of 
chemotherapeutic agents. Calcitriol promotes tumor 
cell sensitivity to several antimetabolites, which in-
terfere with the synthesis of RNA and DNA. Calcitriol 
enhances  cellular  sensitivity  of  human  colon  cancer 
c e l l s   t o   5 -fluorouracil  through  calcium-sensing  re-
ceptor  (23).  When  added  together  or  immediately 
after  ara-C  (cytarabine),  calcitriol  promotes  the  ac-
cumulation of DNA fragments and cytotoxicity (24). 
Calcitriol and cytarabine combination has been used 
in  clinic  as  the  minimally  intensive  chemotherapy, 
and  prolonged  remission  in  elderly  patients  with 
acute myeloid leukemia (AML) and myelodysplastic 
syndrome  (MDS)  (25,  26).  Adenosine  deami-
nase-resistant analog fludarabine synergistically en-
hances  calcitriol-induced  differentiation  of  human 
monoblastic leukemia U937 cells (27). Hydroxyurea, 
cytarabine  or  camptothecin  acts  synergistically  with 
calcitriol to inhibit human monoblastic leukemia U937 
cell  growth  (28).  Hydroxyurea  also  promotes  calci-
triol-mediated U937 cell differentiation (28).  Gemci-
tabine is a widely used antimetabolite, and the com-
bination of gemcitabine and cisplatin is the current 
standard chemotherapy regimen for locally advanced 
and metastatic bladder cancer (29, 30). Calcitriol en-
hances  caspase-dependent  apoptosis and  synergisti-
c a l l y   p r o m o t e s   t h e   a n t i -proliferative effects of gemci-
tabine and cisplatin in human bladder cancer model 
systems  T24  and  UMUC3  (31).  We  have  shown  in 
v i t r o   i n   S C C   c e l l s   t h a t   p 7 3   i s   i m p o r t a n t   i n   c a l c i t r i o l  
antiproliferative  effect;  we  are  also  examining  p73 
status in  vivo  in  human transitional cell carcinoma. 
T h e   e x p r e s s i o n   o f   p 7 3   p r o t e i n   i s   l o w e r   i n   h u m a n  
b l a d d e r   c a n c e r   t i s s u e   c o m p a r e d   w i t h   a d j a c e n t   n o r m a l  
t i s s u e   i n   3   o u t   o f   4   p a i r s   a s   a s s e s s e d   b y   i m m u n o b l o t  
analysis (31). Calcitriol augments p73 protein level in 
T24  and  UMUC3  bladder  cancer  cells,  which  may 
contribute to this growth inhibition (31). Pretreatment Journal of Cancer 2010, 1 
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with calcitriol in combination with gemcitabine and 
cisplatin markedly inhibits T24 tumor growth in nude 
mice (31). Anti-tumor activity of gemcitabine is also 
augmented by calcitriol in Capan-1 human pancreatic 
cancer  model  system,  as  suggested  by  enhanced 
growth  inhibition,  apoptosis, inhibition  of Akt sur-
vival pathway and xenograft tumor growth (32).  
Calcitriol  potentiates  antitumor  activity  of  mi-
crotubule-d i s r u p t i n g   a g e n t s   s u c h   a s   p a c l i t a x e l   (33, 34) 
and docetaxel (35). This  effect  is  associated  with  re-
duced expression level of p21 in prostate cancer cell 
PC3 (33) or increased Bcl-2 phosphorylation in breast 
cancer cells (34),   a n d   m u l t i d r u g   r e s i s t a n c e -associated 
protein  1  (35),  respectively.  Calcitriol  analog 
1,25(OH)2-16-ene-23-yne-19-nor-26,27-F6-D3  (LH)  or 
EB1089  also  potentiates  antitumor  activi t y   o f   p a c l i-
taxel in breast cancer model systems (36). Calcitriol 
analog ILX 23-7553 additively enhances the antitumor 
effects of both adriamycin and ionizing irradiation in 
b r e a s t   t u m o r   c e l l s   M C F -7 through growth inhibition 
and apoptosis induction (37). These substantial data 
suggest  that  the  addition  of  calcitriol  to  multiple 
chemotherapy regimens increases the activity of such 
treatments  and  potentially  a  better  response  rate  to 
the regimens.  
VDR f o r m s   h e t e r o d i m e r   i n   a s s o c i a t i o n   w i t h   R X R .  
RXR  ligand  9-cis-retinoic  acid  (9-cis-RA)  combined 
with calcitriol results in delayed tumor progression in 
the prostate PC3 tumor xenograft model in nude mice 
(38).  This  combination  treatment  results  in  direct 
binding  of  VDR/RXR  heterodimer  to  the  promoter 
region  of  human  telomerase  reverse  transcriptase 
( h T E R T )   w h i c h   i n h i b i t s   t h e   e x p r e s s i o n   o f   h T E R T   a n d  
subsequently leads to decreased telomerase activity in 
prostate  cancer  cells  (38).  Calcitriol  analog 
20-epi-22oxa-24a,26a,27a-tri-homo-1α,25(OH)2D3 
(KH1060)  synergizes  with  9-cis-RA  to  inhibit  the 
growth  and  promote  the  differentiation  of  acute 
promyelocytic leukemia cells NB4 (39) and  myelob-
lastic cells HL-60  (40). T h e   c o m b i n a t i o n   l e a d s   t o   i n-
creased apoptosis which is accompanied by reduced 
Bcl-2 expression and increased Bax expression (39).  
The antitumor activity of calcitriol may also in-
volve histone deacetylation. Combining histone dea-
cetylase  inhibitor  sodium  butyrate  or  trichostatin  A 
with  calcitriol  or  its  analog  LH  or 
1α,25-(OH) 2-16,23E-diene-26,27-hexafluoride-D3  (LT) 
synergistically suppresses calcitriol or analog-induced 
growth inhibition in prostate cancer cell lines LNCaP, 
PC3 and DU145 (41). T h i s   e f f e c t   i s   m e d i a t e d   b y   e n-
hanced  apoptosis  instead  of  induction  of  cell  cycle 
arrest (41). 
Besides chemotherapy, vitamin D is also used in 
combination  with  other  types  of  cancer  treatment. 
Calcitriol  or  its  less  calcaemic  analogue 
19-nor-1α,25-(OH)2D2  acts  synergistically  with  iro-
nizing radiation   t o   i n h i b i t   t h e   g r o w t h   a n d   a p o p t o s i s   o f  
L N C a P   p r o s t a t e   c a n c e r   c e l l s   a n d   p r i m a r y   t u m o r   c e l l s  
(42). EB1089 potentiates the antitumor activity of iro-
nizing radiation partially through increased apoptosis 
i n   b r e a s t   c a n c e r   m o d e l   s y s t e m   M C F -7  (43).  Breast 
cancer  cells  overexpress  one  of  the  NF-κB subunits 
RelB, which promotes cancer cell survival. Calcitriol 
treatment results in reduced mRNA and protein le-
vels of RelB and its target genes survivin, Bcl-2  and 
MnSOD, and sensitizes the breas t   c a n c e r   c e l l s   H s 5 7 8 T  
and NF639 to gamma-irradiation. Overexpression of 
RelB enhances NF639 cells survival following calci-
triol  and  irradiation  treatment  (44).  Calcitriol  pre-
treatment for 24 h enhances the phototoxic response 
of  human  SC C   A 4 3 1   c e l l s   t o   m e t h y l   a m i n o l a e v u l i-
nate-based photodynamic therapy (45).  
Non-specific  cyclooxygenase  (COX)  inhibitors 
acetyl salicylic acid or indomethacin in combination 
with  calcitriol  markedly  induce  differentiation  of 
leukemia cell lines into monocytes and cell cycle ar-
rest at G1 phase (46). Cell differentiation is dependent 
on phosphorylation of Raf1 (46). The combination of 
ibuprofen,  a  non-steroidal  anti-inflammatory  drug 
(NSAID), and calcitriol results in greater growth in-
hibit i o n   a n d   G 1   c e l l   c y c l e   a r r e s t   i n   h u m a n   p r o s t a t e  
c a n c e r   L N C a P   c e l l s   c o m p a r e d   t o   e i t h e r   a g e n t   a l o n e  
(47). A calcitriol analog 22-oxa-1α,25-(OH)2D3,  when 
used  together  with  vitamin  K2,  promotes  leukemia 
cells HL-60 differentiate into monocytes as examined 
b y   m o r p h o l o g y   a n d   c e l l   s u r f a c e   C D 1 4   e x p r e s s i o n   i n   a  
synergistic nature (48). This combination also induces 
c e l l   c y c l e   a r r e s t   a t   G 0 / G 1   p h a s e ;   h o w e v e r ,   i t   s u p-
presses apoptosis compared to vitamin K2 alone (48). 
Carnosic acid, a plant-derived polyphenolic antioxi-
dant, enhances the monocytic differentiation effects of 
calcitriol in human myeloid leukemia cells HL60 (49). 
Decreased  intracellular  reactive  oxygen  species,  in-
creased  intracellular  glutathione,  and  activation  of 
Raf-1/MEK1/ERK1/2 pathway are observed with the 
combination  treatment  (49).  Bryostatin-1,  a  marine 
bryozoan-derived natural compound, has antitumor 
activities  in  both  solid  and  lymphoid  tumors  (50). 
Bryostatin-1 synergizes with calcitriol to induce mo-
nocytic differentiation of NB4 cells (50, 51),   w h i c h   i s  
associated with G1 phase cell cycle arrest, decreased 
cell  growth  and  increased  plastic  adhesion  (50). 
25(OH)D3, when used together with iron deprivation 
agents including iron chelators or transferrin receptor 
antibody A24, induces the differentiation of myeloid 
leukemia  cell  lines  and  primary  myeloblasts  from 
AML  patients  into  monocytes/macrophages  (52). 
These effects are dependent on the increased level of Journal of Cancer 2010, 1 
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reactive  oxygen  species  and  the  activation  of  JNK 
MAPK pathway (52).  
Interaction  of  calcitriol  with  certain  agents  re-
sults in enhanced calcitriol anti-tumor  activity.  Ad-
ministration of dexamethasone (Dex), which reduces 
calcitriol-induced  hypercalcemia,  prior  to  calcitriol 
inhibits SCC cell proliferation compared to calcitriol 
alone  (53). Combined  treatment  with Dex and  calci-
t r i o l   r e d u c e s   S C C   x e n o g r a f t   t u m o r   g r o w t h .   These 
findings are associated with the observations that Dex 
enhances VDR expressio n   i n   S C C   c e l l s   a n d   V D R   l i-
gand  binding  activities  in  tumor  cell  extracts  and 
kidneys but decreases that in intestinal mucosa (53). 
F u r t h e r   s t u d i e s   s h o w   t h a t   t h e   c o m b i n a t i o n   o f   c a l c i t r i o l  
and Dex apoptosis and cell cycle arrest at G0/G1 in 
SCC cells (54). This combination also suppresses the 
activation of Akt and ERK1/2 pathways (54).  
The effect of calcitriol is modulated by its meta-
bolizing enzymes. T h e   p r i m a r y   v i t a m i n   D 3 inactivat-
ing  enzyme  CYP24A1,  a  mitochondrial  cytochrome 
P450, induces calcitriol degradation and thereby inhi-
bits calcitriol biological activity. The broad spectrum 
cytochrome  P450  inhibitor  ketoconazole  (KTZ)  or  a 
specific CYP24A1 inhibitor RC2204, which effectively 
inhibits  the  expression  and  enzyme  activity  of 
CYP24A1 in PC3 cells and mice kidney tissue, syner-
gistically inhibits the anti-proliferative effect of calci-
triol in human prostate PC3 cells (55). Dex  is  admi-
nistered  together  with  KTZ  to  minimize  calci-
triol-mediated  hypercalcemia. Enhanced apoptosis is 
o b s e r v e d   w h i c h   d o e s   n o t   i n v o l v e   c a s p a s e   3  activation 
but  the  translocation  of  apoptosis  inducing  factor 
(AIF)  to  the  nucleus. Calcitriol and ketoconazle/Dex 
combination enhances the growth inhibition observed 
with calcitriol alone in PC3 xenograft tumor mouse 
model (55). KTZ also potentiates the anti-proliferative 
effect  of  calcitriol  or  its  analog  EB1089  in  prostate 
cancer  cells  (56).  An  imidazole  derivative  liarozole 
inhibits CYP24 activity in prostate cancer cells DU145 
and  thus  sensitizes  these  cells  to  calcitriol-mediated 
growth inhibition, which is associated with increased 
VDR expression (57).  
RRR-alpha-v i t a m i n   E   s u c c i n a t e   ( V E S ) ,   o n e   o f   t h e  
m o s t   e f f e c t i v e   v i t a m i n   E   f o r m s ,   i n d u c e s   V D R   e x p r e s-
sion in prostate cancer cells (58). Pretreatment  with 
VES  synergistically  enhances  calcitriol-mediated 
g r o w t h   i n h i b i t i o n   o f   p r o s t a t e   c a n c e r   c e l l s   i n   v i t r o   a n d  
r e d u c e s   t h e   r a t e   o f   p r o s t a t e   c a n c e r   x e n o g r a f t   t u m o r  
growth (58), which allows for a low-dose calcitriol to 
be administered. A glutathione-depleting compound, 
menadione,  sensitizes  breast  cancer  cells  MCF-7  to 
calcitriol-mediated growth inhibition, which may be 
caused, at least in part, by the increased oxidative 
stress,  as  shown  by  enhanced  ROS  production  (59). 
Genistein,  an  isoflavone  found  in  soybeans  and  a 
number of plants, in combination with calcitriol, in-
h i b i t s   c e l l   g r o w t h   i n   h u m a n   p r o s t a t e   L N C a P   c e l l s ,  
which is dependent on increased expression of p21 
and associated with increased VDR expression (60). 
Another  study  shows  that  genistein  and  calcitriol 
further  reduce  prostate  DU145  cell  proliferation 
compared to either agent alone (61). The mechanisms 
f o r   t h i s   e f f e c t   m a y   i n v o l v e   t h e   i n d u c t i o n   o f   m R N A  
expression and enzyme activity of CYP24 by genistein 
which  leads  to  prolonged  half-life of calcitriol (61). 
Increased expression of VDR protein, VDR transcrip-
t i o n a l   a c t i v i t y ,   a n d   t h e   e x p r e s s i o n   o f   V D R   t a r g e t   g e n e s  
a r e   a l s o   o b s e r v e d   i n   t h e   c o m b i n a t i o n   t r e a t m e n t   g r o u p  
(61). A medicinal herb ginseng (Panax ginseng C.A. 
Meyer,  Araliaceae)  promotes  calcitriol-induced  the 
differentiation  of  leukemia  cells  HL-60  into  mono-
cytes as assessed by expression levels of CD14 and 
CD11b  (62).  T h i s   e f f e c t   m a y   b e   m e d i a t e d   b y   t h e  
ERK1/2 and PKC, but not PI3K pathway (62).  
Phosphorylated prolactin (PRL) antagonizes the 
proliferation  promoting  effect  of  unmodified  PRL. 
M o l e c u l a r   m i m i c r y   o f   n a t u r a l l y   p h o s p h o r y l a t e d   h u-
man  PRL  at  the  major  phosphorylation  site  S179, 
S179D  (PRL),  sensitizes  relatively  vitamin 
D-insensitive prostate cancer cells DU-145 and PC3 to 
calcitriol-mediated  anti-proliferative  effect  and 
apoptosis,  which  is  associated  with  increased  VDR 
and p21 expression (63). Secreted protein acidic and 
rich in cysteine (SPARC; osteonectin, BM-40), a family 
member  of  matricellular  proteins  including  throm-
bospondins, tenascin, and osteopontin, may serve as a 
tumor  suppressor  (64).  Compared  with  parental 
MIP101  colorectal  cancer  cells,  calcitriol  markedly 
reduces cell growth and enhances calcitriol alone- or 
calcitriol+fluorouracil-induced  apoptosis  in 
SPARC-overexpressing  MIP101  cells  (64).  Calcitriol 
treatment also suppresses the phosphorylation of Akt 
and the expression of Bcl-2 family member BAD (64). 
C a l c i t r i o l   h a s   b e e n   u t i l i z e d   i n   a   n u m b e r   o f   c l i n i-
cal studies, either alone or in combination with Dex or 
cytotoxic agents, which has been reviewed (65, 66). It 
is important to emphasize that anti-tumor activity of 
calcitriol is dependent on its dose and exposure ac-
cording to preclinical studies. E x p o s u r e   t o   h i g h   c o n-
centrations  of  calcitriol  is  necessary  to  achieve  an-
ti-tumor  results.  Calcitriol  or  its  analog  Ro23-7553 
delays  SCC  xenograft  tumor  growth  in  a  dose  de-
pendent manner (67). Calcitriol of 2.5 µg/mouse ad-
m i n i s t e r e d   t w i c e   a   w e e k   r e s u l t s   i n   a   m a r k e d l y  
stronger  tumor  suppression  compared  with  once  a 
week  regimen  in  human  pancreatic  cancer  model 
system Capan-1 (32). Pharmacokinectic  (PK)  studies 
indicate that calcitriol of 0.125 µg/mouse results in a Journal of Cancer 2010, 1 
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Cmax >   1 0 . 0   n g / m l   a n d   A U C   >   4 0 . 0   n g   h / m L   i n   n o r m a l  
mice (68), which exceeds the concentration needed for 
calcitriol anti-tumor activity in vitro.  
Although  multiple  clinical  studies  have  been 
conducted with calci t r i o l   o r   i t s   a n a l o g s ,   t h e   a n t i -tumor 
results are largely disappointing. T h i s   m a y   b e   d u e   t o  
t h e   f a c t   t h a t   c a l c i t r i o l   o r   i t s   a n a l o g s   h a s   b e e n   u s e d   a t  
m u c h   l o w e r   d o s e s   t h a n   m a x i m u m   t o l e r a t e d   d o s e  
(MTD) with the concern of dose-limiting hypercalce-
mia  (69,  70). We and others demonstrate that suffi-
cient doses of calcitriol to achieve exposure similar to 
those seen in preclinical models can be safely admi-
nistered  by  high  dose  intermittent  regimen  (once 
weekly or QDx3 weekly) (69, 71-73). A   r e c e n t   p h a s e   I  
clinical  trial demonstrates  that  the MTD  of  calcitriol 
(i.v.) is 74 µg/week when administered with gefitinib 
(70). The Cmax of calcitriol at the MTD is 6.68 ± 1.42 
ng/ml (16 ± 3.40 nmol/L), which is much higher than 
the dose needed to elicit anti-t u m o r   e f f e c t   i n   p r e c l i n i-
cal studies (70). T h e   a r e a   u n d e r   t h e   c u r v e   ( A U C )   o f  
calcitriol at the MTD is 35.65 ± 8.01 ng h/mL (70). In 
comparison, 75 µg   o f   D N 1 0 1 ,   a   w e e k l y   o r a l   f o r m u l a-
tion of calcitriol, results in a lower Cmax (3.8 nmol/L) 
b u t   s i m i l a r   A U C   ( 3 8 . 4   n g   h / m L )   (74). These results 
s h o w   t h a t   h i g h   d o s e s   o f   c a l c i t r i o l   c a n   b e   a d m i n i s t e r e d  
alone or in combination with other agents to elicit or 
enhance the anti-tumor effects. 
Summary 
In  summary,  calcitriol  has  shown  potential  in 
enhancing the antitumor activities of a variety of cy-
totoxic  or  differentiating  agents.  The  combination 
treatment studies with calcitriol do provide evidence 
a n d   s u p p o r t   f o r   t h e   c o n t i n u e d   s t u d y   o f   c a l c i t r i o l   i n  
cancer chemotherapies.  
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